Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

DelveInsight's "TRYVIO/JERAYGO Market Size, Forecast, and Market Insight Report" highlights the details around TRYVIO/JERAYGO ...

Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria ...

TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension inadequately controlled by existing treatments. TRYVIO ...

Research led by Mirvie Inc. has discovered a molecular signal in blood samples that can predict preeclampsia and related conditions months before clinical symptoms appear. Findings suggest a new ...

Mendelian randomization (MR) represents a valuable methodology to address the causal relationships between an exposure and an outcome. In MR studies, instrumental variables associated with the ...

In a transformative review, small noncoding RNAs (sncRNAs) have emerged as pivotal regulators in the complex landscape of cardiovascular diseases.

A new systematic review identifies 17 modifiable risk factors shared by stroke, dementia, and late-life depression — offering ...

Panelists discuss how patients with immunoglobulin A (IgA) nephropathy typically present with microscopic or gross hematuria, often during upper respiratory infections, along with variable proteinuria ...

TNF Pharmaceuticals, Inc. ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health ...